Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sánchez-Rovira P, Ramos M, Rojo F, Burgués O, Carrasco E, Caballero R, Porras I, Tibau A, Cámara MC, Lluch A. Alba E, et al. Among authors: albanell j. Br J Cancer. 2014 Mar 4;110(5):1139-47. doi: 10.1038/bjc.2013.831. Epub 2014 Jan 23. Br J Cancer. 2014. PMID: 24457911 Free PMC article. Clinical Trial.
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.
Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, Sanchez-Rovira P, Plazaola A, Lopez Garcia-Asenjo JA, Bermejo B, Carrasco E, Lluch A; GEICAM. Alba E, et al. Among authors: albanell j. Ann Oncol. 2012 Dec;23(12):3069-3074. doi: 10.1093/annonc/mds132. Epub 2012 Jun 6. Ann Oncol. 2012. PMID: 22674146 Free article. Clinical Trial.
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study.
Alba E, Chacon JI, Lluch A, Anton A, Estevez L, Cirauqui B, Carrasco E, Calvo L, Segui MA, Ribelles N, Alvarez R, Sanchez-Muñoz A, Sanchez R, Garcia-Asenjo JA, Rodriguez-Martin C, Escudero MJ, Albanell J. Alba E, et al. Among authors: albanell j. Breast Cancer Res Treat. 2012 Nov;136(2):487-93. doi: 10.1007/s10549-012-2100-y. Epub 2012 Oct 9. Breast Cancer Res Treat. 2012. PMID: 23053638 Clinical Trial.
Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Prat A, et al. Among authors: albanell j. Br J Cancer. 2014 Oct 14;111(8):1532-41. doi: 10.1038/bjc.2014.444. Epub 2014 Aug 7. Br J Cancer. 2014. PMID: 25101563 Free PMC article.
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Albanell J, Martínez MT, Ramos M, O'Connor M, de la Cruz-Merino L, Santaballa A, Martínez-Jañez N, Moreno F, Fernández I, Alarcón J, Virizuela JA, de la Haba-Rodríguez J, Sánchez-Rovira P, González-Cortijo L, Margelí M, Sánchez-Muñoz A, Antón A, Casas M, Bezares S, Rojo F. Albanell J, et al. Eur J Cancer. 2022 Jan;161:26-37. doi: 10.1016/j.ejca.2021.11.010. Epub 2021 Dec 11. Eur J Cancer. 2022. PMID: 34902765 Free article. Clinical Trial.
Current controversies in the management of early breast cancer.
Estévez LG, Martín M, Alba E, Colomer R, Lobo F, Lluch A, Adrover E, Albanell J, Barnadas A, García-Mata J, Llombart A, Muñoz M, Rodríguez C, Sánchez-Rovira P, Seguí MA, Tusquets I. Estévez LG, et al. Among authors: albanell j. Clin Transl Oncol. 2007 Jun;9(6):375-84. doi: 10.1007/s12094-007-0070-z. Clin Transl Oncol. 2007. PMID: 17594952 Review.
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A. Albanell J, et al. Ann Oncol. 2012 Mar;23(3):625-631. doi: 10.1093/annonc/mdr278. Epub 2011 Jun 6. Ann Oncol. 2012. PMID: 21652577 Free article.
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).
González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortés J, de la Haba J, López-Vega JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez Á, Rodríguez CA, Ruíz A, Llombart A. González A, et al. Among authors: albanell j. Clin Transl Oncol. 2017 May;19(5):616-624. doi: 10.1007/s12094-016-1571-4. Epub 2016 Nov 16. Clin Transl Oncol. 2017. PMID: 27853985 Review.
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antón A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J. Tabernero J, et al. Among authors: albanell j. Ann Oncol. 2004 Sep;15(9):1358-65. doi: 10.1093/annonc/mdh349. Ann Oncol. 2004. PMID: 15319242 Free article. Clinical Trial.
263 results